FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025772696> ?p ?o ?g. }

• W2025772696 endingPage "458" @default.
• W2025772696 startingPage "452" @default.
• W2025772696 abstract "Objective Farletuzumab is a humanized monoclonal antibody to folate receptor-α, which is over-expressed in most epithelial ovarian cancers but largely absent on normal tissue. We evaluated clinical activity of farletuzumab, alone and combined with chemotherapy, in women with first-relapse, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancers. Methods Fifty-four eligible subjects received open-label farletuzumab weekly, single agent or combined with carboplatin (AUC5–6) and taxane (paclitaxel 175 mg/m2 or docetaxel 75 mg/m2), every 21 days for 6 cycles, followed by farletuzumab maintenance until progression. Twenty-eight subjects with asymptomatic CA125 relapse received single-agent farletuzumab and could receive platinum/taxane chemotherapy plus farletuzumab after single-agent progression. Twenty-six subjects with symptomatic relapse entered the combination arm directly; 21 subjects entered after single agent. Primary endpoints included normalized CA125 and Overall Response Rate (ORR). Duration of each subject's second progression-free interval (PFI2) was compared with her own first response interval (PFI1). Results Farletuzumab was well-tolerated as single agent, without additive toxicity when administered with chemotherapy. Of 47 subjects who received farletuzumab with chemotherapy, 38 (80.9%) normalized CA125. In 9/42 (21%) evaluable subjects, PFI2 was ≥ PFI1, better than the historical rate (3%). There was a high response rate among subjects with PFI1 <12 months (75%), comparable to that in subjects with PFI1 ≥12 months (84%). Complete or partial ORR was 75% with combination therapy. Conclusion Based on this study, farletuzumab with carboplatin and taxane may enhance the response rate and duration of response in platinum-sensitive ovarian cancer patients with first relapse after remission of 6–18 months." @default.
• W2025772696 created "2016-06-24" @default.
• W2025772696 creator A5000669563 @default.
• W2025772696 creator A5009234043 @default.
• W2025772696 creator A5014378398 @default.
• W2025772696 creator A5057077088 @default.
• W2025772696 creator A5090143508 @default.
• W2025772696 date "2013-06-01" @default.
• W2025772696 modified "2023-10-14" @default.
• W2025772696 title "Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer" @default.
• W2025772696 cites W1570168056 @default.
• W2025772696 cites W1971341208 @default.
• W2025772696 cites W1992819900 @default.
• W2025772696 cites W1993012864 @default.
• W2025772696 cites W2006213902 @default.
• W2025772696 cites W2015217255 @default.
• W2025772696 cites W2016179096 @default.
• W2025772696 cites W2052282900 @default.
• W2025772696 cites W2055437192 @default.
• W2025772696 cites W2076668534 @default.
• W2025772696 cites W2104998982 @default.
• W2025772696 cites W2105782281 @default.
• W2025772696 cites W2109919831 @default.
• W2025772696 cites W2112644262 @default.
• W2025772696 cites W2121322385 @default.
• W2025772696 cites W2126333580 @default.
• W2025772696 cites W2128868545 @default.
• W2025772696 cites W2136753100 @default.
• W2025772696 cites W2137591261 @default.
• W2025772696 cites W2138035969 @default.
• W2025772696 cites W2139248078 @default.
• W2025772696 cites W2143294276 @default.
• W2025772696 cites W2151050516 @default.
• W2025772696 cites W2158734599 @default.
• W2025772696 cites W2162114522 @default.
• W2025772696 cites W2330814896 @default.
• W2025772696 cites W4293241248 @default.
• W2025772696 doi "https://doi.org/10.1016/j.ygyno.2013.03.002" @default.
• W2025772696 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23474348" @default.
• W2025772696 hasPublicationYear "2013" @default.
• W2025772696 type Work @default.
• W2025772696 sameAs 2025772696 @default.
• W2025772696 citedByCount "128" @default.
• W2025772696 countsByYear W20257726962012 @default.
• W2025772696 countsByYear W20257726962013 @default.
• W2025772696 countsByYear W20257726962014 @default.
• W2025772696 countsByYear W20257726962015 @default.
• W2025772696 countsByYear W20257726962016 @default.
• W2025772696 countsByYear W20257726962017 @default.
• W2025772696 countsByYear W20257726962018 @default.
• W2025772696 countsByYear W20257726962019 @default.
• W2025772696 countsByYear W20257726962020 @default.
• W2025772696 countsByYear W20257726962021 @default.
• W2025772696 countsByYear W20257726962022 @default.
• W2025772696 countsByYear W20257726962023 @default.
• W2025772696 crossrefType "journal-article" @default.
• W2025772696 hasAuthorship W2025772696A5000669563 @default.
• W2025772696 hasAuthorship W2025772696A5009234043 @default.
• W2025772696 hasAuthorship W2025772696A5014378398 @default.
• W2025772696 hasAuthorship W2025772696A5057077088 @default.
• W2025772696 hasAuthorship W2025772696A5090143508 @default.
• W2025772696 hasConcept C121608353 @default.
• W2025772696 hasConcept C126322002 @default.
• W2025772696 hasConcept C141071460 @default.
• W2025772696 hasConcept C143998085 @default.
• W2025772696 hasConcept C2776694085 @default.
• W2025772696 hasConcept C2777292972 @default.
• W2025772696 hasConcept C2777511904 @default.
• W2025772696 hasConcept C2778239845 @default.
• W2025772696 hasConcept C2780427987 @default.
• W2025772696 hasConcept C2781190966 @default.
• W2025772696 hasConcept C2781451048 @default.
• W2025772696 hasConcept C3019864225 @default.
• W2025772696 hasConcept C530470458 @default.
• W2025772696 hasConcept C71924100 @default.
• W2025772696 hasConcept C90924648 @default.
• W2025772696 hasConceptScore W2025772696C121608353 @default.
• W2025772696 hasConceptScore W2025772696C126322002 @default.
• W2025772696 hasConceptScore W2025772696C141071460 @default.
• W2025772696 hasConceptScore W2025772696C143998085 @default.
• W2025772696 hasConceptScore W2025772696C2776694085 @default.
• W2025772696 hasConceptScore W2025772696C2777292972 @default.
• W2025772696 hasConceptScore W2025772696C2777511904 @default.
• W2025772696 hasConceptScore W2025772696C2778239845 @default.
• W2025772696 hasConceptScore W2025772696C2780427987 @default.
• W2025772696 hasConceptScore W2025772696C2781190966 @default.
• W2025772696 hasConceptScore W2025772696C2781451048 @default.
• W2025772696 hasConceptScore W2025772696C3019864225 @default.
• W2025772696 hasConceptScore W2025772696C530470458 @default.
• W2025772696 hasConceptScore W2025772696C71924100 @default.
• W2025772696 hasConceptScore W2025772696C90924648 @default.
• W2025772696 hasIssue "3" @default.
• W2025772696 hasLocation W20257726961 @default.
• W2025772696 hasLocation W20257726962 @default.
• W2025772696 hasOpenAccess W2025772696 @default.
• W2025772696 hasPrimaryLocation W20257726961 @default.
• W2025772696 hasRelatedWork W1980931076 @default.
• W2025772696 hasRelatedWork W1990296886 @default.

• next